Cardiovascular Disease

Inflammation’s ASCVD Risks and Potential

New data reveals that inflammation is a stronger predictor of future cardiovascular events and death than cholesterol among patients who take statins, suggesting that treatment regimens that target both LDL and vascular inflammation are more likely to reduce atherosclerotic risk compared to treatments that only target LDL.

The Lancet meta-analysis used 32k patients’ data from the PROMINENT, REDUCE-IT, and STRENGTH trials, all of whom had or were at high risk of ASCVD and were already taking statins. Across the three trial groups, baseline levels of high-sensitivity CRP (hsCRP) and LDL-C were “almost identical.” The study was also authored by leaders of the three original trials.

After adjustments, comparisons of patients in the highest and lowest hsCRP quartiles seemed to solidify residual inflammatory risk’s association with: 

  • Major adverse cardiovascular events (HR: 1.31)
  • Cardiovascular mortality (HR: 2.68)
  • All-cause mortality (HR: 2.42)

Meanwhile, patients in the highest and lowest LDL-C quartiles revealed that residual cholesterol risk had a “neutral”  association with MACE and a “low magnitude” associated with mortality: 

  • Major adverse cardiovascular events (HR: 1.07)
  • Cardiovascular mortality (HR: 1.27)
  • All-cause mortality (HR: 1.16)

The Takeaway

We’ve seen growing evidence that patients on statins can benefit from adjunctive LDL-lowering therapies, but this study gives a strong argument for combining LDL-reducing and inflammation-reducing therapies. If proven through future trials, that could have a major impact on ASCVD care.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Practices September 18, 2025

What Cardiologists Say vs. What Patients Hear September 18, 2025

Cardiovascular risk communication might be failing patients when they need it most, after the HARIPA study revealed significant disconnects between patient and physician perceptions of future cardiovascular risk and procedural complications. The HARIPA study surveyed cardiology inpatients and their physicians from October 2022 to March 2023, using structured questionnaires to assess risk perception and communication […]

Digital Health September 15, 2025

TRICORDER Shows Potential of AI Stethoscopes September 15, 2025

Results from the massive TRICORDER study suggest Eko Health’s AI-powered stethoscopes could change the way primary care providers perform cardiac screening, potentially catching thousands more patients for cardiologists to treat. The TRICORDER study results encompassed 205 NHS GP practices over 12 months, with nearly 1,000 providers performing more than 12.8k AI-stethoscope exams in routine care […]

Cardiology September 11, 2025

Cardiac Wire’s ASE 2025 Takeaways September 11, 2025

The American Society of Echocardiography left an echo this year in Music City as it celebrated its 50th year. Among the studies and products unveiled at ASE 2025, here are Cardiac Wire’s top five takeaways from the meeting. Premium Echo Has Found its Stride – Although most typically think of ultrasound as a lower cost […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!